Payment overview · 2025
General Payments
$609.36
6 reported records · 4 companies
Healthcare provider profile · identity verified
Larry Hunt
Allopathic & Osteopathic Physicians|Internal Medicine · BIRMINGHAM, AL · NPI 1275568966
Verified facts
What the public records show
CMS Open Payments records show Larry Hunt received $609.36 in general payments during 2025 across 6 reported records.
Axsome Therapeutics, Inc. accounted for 40.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $247.06 | 40.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $134.74 | 22.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $131.16 | 21.5% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $96.40 | 15.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $609.36 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $247.06 | 2 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $131.16 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $131.16 | 1 | 2025 |
Source payment records
|
|||||
| Tryvio Normalized: tryvio |
Drug | IDORSIA PHARMACEUTICALS US INC | $96.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
195 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 415 | 135 |
| Atorvastatin Calcium | Atorvastatin Calcium | 343 | 109 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 312 | 54 |
| Gabapentin | Gabapentin | 274 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 264 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 75 |
| Losartan Potassium | Losartan Potassium | 203 | 69 |
| Irbesartan | Irbesartan | 198 | 52 |
| Ozempic | Semaglutide | 195 | 30 |
| Eliquis | Apixaban | 188 | 38 |
| Lisinopril | Lisinopril | 180 | 58 |
| Metformin Hcl Er | Metformin Hcl | 176 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 58 |
| Clonazepam | Clonazepam | 155 | 28 |
| Omeprazole | Omeprazole | 150 | 48 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 147 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 132 | 40 |
| Tramadol Hcl | Tramadol Hcl | 127 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 34 |
| Simvastatin | Simvastatin | 114 | 34 |
| Alprazolam | Alprazolam | 113 | 24 |
| Mounjaro | Tirzepatide | 111 | 22 |
| Furosemide | Furosemide | 110 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 36 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 108 | 40 |
| Carvedilol | Carvedilol | 105 | 40 |
| Trazodone Hcl | Trazodone Hcl | 104 | 29 |
| Spironolactone | Spironolactone | 100 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 38 |
| Glimepiride | Glimepiride | 95 | 32 |
| Allopurinol | Allopurinol | 94 | 32 |
| Famotidine | Famotidine | 90 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 33 |
| Lorazepam | Lorazepam | 78 | 27 |
| Metformin Hcl | Metformin Hcl | 77 | 26 |
| Chlorthalidone | Chlorthalidone | 76 | 25 |
| Potassium Chloride | Potassium Chloride | 74 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 23 |
| Meloxicam | Meloxicam | 67 | 21 |
| Ezetimibe | Ezetimibe | 66 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 64 | 18 |
| Sertraline Hcl | Sertraline Hcl | 62 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 17 |
| Ondansetron Odt | Ondansetron | 59 | 28 |
| Tresiba Flextouch U-100 | Insulin Degludec | 58 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 19 |
| Fluconazole | Fluconazole | 57 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 21 |
| Candesartan Cilexetil | Candesartan Cilexetil | 55 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 19 |
| Trulicity | Dulaglutide | 53 | suppressed |
| Mirtazapine | Mirtazapine | 52 | 18 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 51 | 12 |
| Bupropion Xl | Bupropion Hcl | 50 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 14 |
| Clonidine | Clonidine | 47 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 47 | 15 |
| Jardiance | Empagliflozin | 47 | 18 |
| Colestipol Hcl | Colestipol Hcl | 46 | 12 |
| Prednisone | Prednisone | 46 | 17 |
| Januvia | Sitagliptin Phosphate | 45 | 13 |
| Azithromycin | Azithromycin | 44 | 26 |
| Montelukast Sodium | Montelukast Sodium | 44 | 19 |
| Methocarbamol | Methocarbamol | 43 | 19 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Finasteride | Finasteride | 40 | 13 |
| Buspirone Hcl | Buspirone Hcl | 39 | 12 |
| Diazepam | Diazepam | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | 12 |
| Linzess | Linaclotide | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 13 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 16 |
| Premarin | Estrogens, Conjugated | 28 | suppressed |
| Eplerenone | Eplerenone | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | 11 |
| Telmisartan | Telmisartan | 24 | suppressed |
| Estradiol | Estradiol | 23 | 12 |
| Humalog | Insulin Lispro | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Cefdinir | Cefdinir | 22 | 21 |
| Glipizide Er | Glipizide | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 17 |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Nateglinide | Nateglinide | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 14 |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Diovan Hct | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $609.36 · 6 records | Axsome Therapeutics, Inc. | Auvelity, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Tryvio | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error